全文获取类型
收费全文 | 201747篇 |
免费 | 18745篇 |
国内免费 | 8767篇 |
专业分类
耳鼻咽喉 | 2588篇 |
儿科学 | 4765篇 |
妇产科学 | 2195篇 |
基础医学 | 34987篇 |
口腔科学 | 7267篇 |
临床医学 | 15407篇 |
内科学 | 26189篇 |
皮肤病学 | 4576篇 |
神经病学 | 9876篇 |
特种医学 | 6024篇 |
外国民族医学 | 129篇 |
外科学 | 26408篇 |
综合类 | 30411篇 |
现状与发展 | 48篇 |
预防医学 | 5378篇 |
眼科学 | 3642篇 |
药学 | 14329篇 |
37篇 | |
中国医学 | 5905篇 |
肿瘤学 | 29098篇 |
出版年
2024年 | 155篇 |
2023年 | 2627篇 |
2022年 | 3584篇 |
2021年 | 6500篇 |
2020年 | 6209篇 |
2019年 | 6020篇 |
2018年 | 6399篇 |
2017年 | 6598篇 |
2016年 | 7103篇 |
2015年 | 8113篇 |
2014年 | 12083篇 |
2013年 | 13328篇 |
2012年 | 11393篇 |
2011年 | 12852篇 |
2010年 | 10768篇 |
2009年 | 10536篇 |
2008年 | 10921篇 |
2007年 | 11178篇 |
2006年 | 10206篇 |
2005年 | 9546篇 |
2004年 | 8346篇 |
2003年 | 7146篇 |
2002年 | 5854篇 |
2001年 | 5025篇 |
2000年 | 4316篇 |
1999年 | 3721篇 |
1998年 | 3024篇 |
1997年 | 2988篇 |
1996年 | 2575篇 |
1995年 | 2593篇 |
1994年 | 2324篇 |
1993年 | 1893篇 |
1992年 | 1586篇 |
1991年 | 1481篇 |
1990年 | 1154篇 |
1989年 | 1059篇 |
1988年 | 1004篇 |
1987年 | 814篇 |
1986年 | 773篇 |
1985年 | 968篇 |
1984年 | 839篇 |
1983年 | 573篇 |
1982年 | 646篇 |
1981年 | 519篇 |
1980年 | 451篇 |
1979年 | 384篇 |
1978年 | 296篇 |
1977年 | 232篇 |
1976年 | 168篇 |
1973年 | 76篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的通过测量锁骨钩钢板内固定术后患者影像学资料,分析发生肩峰骨侵蚀的原因是否与钢板钩-肩峰匹配度相关。
方法回顾性分析2015年8月1日至2018年8月31日期间在上海市浦东医院骨科就诊的210例患者的影像学资料,210例患者均因肩锁关节脱位或锁骨远端骨折行锁骨钩钢板内固定治疗,其中男110例、女100例;年龄24~76岁,平均(44.60±8.75)岁;肩锁关节脱位70例,锁骨远端骨折140例。测量术后及终末随访患者肩锁关节正位X线片相关数据,按锁骨钩钢板术后是否发生肩峰骨侵蚀,将纳入患者分为3组:无骨侵蚀组(A组)、伴钢板钩移位骨侵蚀组(B组)、不伴移位的骨侵蚀组(C组),分别测量钢板钩-肩峰的匹配度(β),统计分析术后发生肩峰骨侵蚀与钢板钩-肩峰匹配度之间的关系。
结果纳入研究的210例患者术后随访24~64周,平均(32.0±6.5)周。A组患者115例,B组患者54例,C组患者41例。A组匹配度β(3.72±0.48)mm与B组β1(6.91±0.84)mm比较差异有统计学意义(P<0.05);A组匹配度β(3.72±0.48)mm与C组β2(5.88±0.65)mm比较差异有统计学意义(P<0.05);B组匹配度β1(6.91±0.84)mm与C组β2(5.88±0.65)mm比较差异有统计学意义(P<0.05)。
结论锁骨钩钢板内固定术后是否发生肩峰骨侵蚀与钢板钩-肩峰匹配度β存在明显相关性,钢板钩与肩峰之间的匹配度越好,β值越小,发生肩峰骨侵蚀的可能性更小。 相似文献
2.
3.
目的探讨肺癌患者化疗后的癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和鳞状上皮细胞癌抗原(SCC-Ag)表达变化。方法选取2017年5月至2020年2月间南京市六合区人民医院收治的100例肺癌患者,将这些患者作为肺癌组,另随机选取同期100例健康体检人员作为健康组。统计分析两组人员化疗前的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗成功患者化疗前后的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗失败患者化疗前后的血清NSE、CEA、SCC-Ag表达水平。结果肺癌组患者化疗前的血清NSE、CEA和SCC-Ag表达水平均高于健康组,差异均有统计学意义(均P <0.05)。肺癌组化疗成功患者化疗后的血清NSE、CEA和SCC-Ag表达水平均低于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。肺癌组化疗失败患者化疗后的血清NSE、CEA、SCC-Ag表达水平均高于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。结论对肺癌患者的NSE、CEA、SCC-Ag表达水平进行检测能够将化疗效果有效反映出来,进而有效指导临床的下一步治疗工作,从而有效改善患者预后。 相似文献
4.
5.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
6.
7.
Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder. 相似文献
8.
Jos B. Poell Leon J. Wils Arjen Brink Ralf Dietrich Christine Krieg Eunike Velleuer Ilkay Evren Elisabeth R. Brouns Jan G. de Visscher Elisabeth Bloemena Bauke Ylstra Ruud H. Brakenhoff 《International journal of cancer. Journal international du cancer》2023,152(2):227-238
Oral squamous cell carcinomas (OSCCs) develop in genetically altered epithelium in the mucosal lining, also coined as fields, which are mostly not visible but occasionally present as white oral leukoplakia (OL) lesions. We developed a noninvasive genetic assay using next-generation sequencing (NGS) on brushed cells to detect the presence of genetically altered fields, including those that are not macroscopically visible. The assay demonstrated high accuracy in OL patients when brush samples were compared with biopsies as gold standard. In a cohort of Fanconi anemia patients, detection of mutations in prospectively collected oral brushes predicted oral cancer also when visible abnormalities were absent. We further provide insight in the molecular landscape of OL with frequent changes of TP53, FAT1 and NOTCH1. NGS analysis of noninvasively collected samples offers a highly accurate method to detect genetically altered fields in the oral cavity, and predicts development of OSCC in high-risk individuals. Noninvasive genetic screening can be employed to screen high-risk populations for cancer and precancer, map the extension of OL lesions beyond what is visible, map the oral cavity for precancerous changes even when visible abnormalities are absent, test accuracy of promising imaging modalities, monitor interventions and determine genetic progression as well as the natural history of the disease in the human patient. 相似文献
9.
10.